Physician profile
Regina E Doherty
NPI 1972041630
$3,415.73
in general payments reported to CMS, 2019-2025
39 companies · $680 in 2025
The $680 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $712 · 2022: $294 · 2023: $571 · 2024: $1,159 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,409.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $327.12 | 2021 | |
| Abbvie INC. | $278.15 | 2021-2025 | |
| Janssen Biotech, INC. | $253.01 | 2022-2024 | Erleada, Akeega, Balversa |
| Tolmar, INC. | $225.04 | 2024-2025 | Eligard, Jatenzo |
| Progenics Pharmaceuticals, INC. | $206.73 | 2023-2025 | Pylarify |
| Bayer Healthcare Pharmaceuticals INC. | $185.14 | 2024-2025 | |
| Antares Pharma, INC. | $148.30 | 2024-2025 | Xyosted |
| Endo Pharmaceuticals INC. | $136.57 | 2023 | Xiaflex, Aveed |
| Janssen Scientific Affairs, LLC | $134.17 | 2022 | |
| Glaxosmithkline, LLC. | $122.40 | 2021 | |
| Pfizer INC. | $122.24 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $115.72 | 2023-2025 | Orgovyx, Gemtesa |
| Hollister Incorporated | $115.35 | 2023-2024 | Vapro Pocket, Infyna Chic |
| Novartis Pharmaceuticals Corporation | $111.52 | 2024-2025 | |
| Abc Home Medical Supply, INC. | $109.84 | 2024 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $103.59 | 2025 | |
| Amgen INC. | $101.78 | 2021-2023 | Xgeva |
| Astellas Pharma US INC | $99.61 | 2023-2024 | Xtandi |
| Exelixis INC. | $82.31 | 2023 | Cabometyx |
| Myriad Genetic Laboratories, INC. | $43.27 | 2022-2023 | Prolaris |
| Kowa Pharmaceuticals America, INC. | $32.00 | 2022-2023 | Seglentis |
| Dendreon Pharmaceuticals LLC | $30.08 | 2024 | Provenge |
| Ipsen Biopharmaceuticals, INC | $29.65 | 2021 | |
| Seagen INC. | $29.30 | 2021 | |
| Eisai INC. | $29.14 | 2021 | |
| Tempus Ai, INC | $23.61 | 2025 | Xt Cdx |
| 180 Medical, INC. | $22.57 | 2024 | |
| Accord Healthcare, INC. | $21.15 | 2022 | |
| Axogen | $20.50 | 2025 | Axoguard Ha+ Nerve Protector |
| Merck Sharp & Dohme LLC | $18.91 | 2024 | Keytruda, Welireg |
| Immunitybio, INC. | $18.26 | 2024 | |
| Boston Scientific Corporation | $17.82 | 2022 | |
| Celgene Corporation | $16.40 | 2024 | Reblozyl |
| Astrazeneca Pharmaceuticals LP | $14.99 | 2021 | |
| Taiho Oncology, INC. | $14.56 | 2022 | |
| Welch Allyn | $14.55 | 2021 | |
| Blue Earth Diagnostics | $13.60 | 2024 | |
| Avation Medical, INC. | $13.42 | 2024 | Vivally |
| Pharmacyclics LLC, An Abbvie Company | $13.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Regina Doherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.